Trial Profile
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Cardiovascular disorders; Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Acronyms PIONEER 6; PIONEER6
- Sponsors Novo Nordisk
- 26 Jun 2023 Results using individual-level participant data from LEADER , SUSTAIN 6 and PIONEER 6 , comparing cardiovascular (CV) protective effect of liraglutide vs semaglutide in subjects with type 2 diabetes, presented at the 83rd Annual Scientific Sessions of the American Diabetes Association
- 01 Apr 2023 Results of pooled post hoc analysis (n=6480 from two studies SUSTAIN 6/PIONEER 6) assessing the effects of semaglutide versus placebo on eGFR decline published in the Kidney International
- 23 Sep 2022 Results of pooled post-hoc analysis from two clinical studies: SUSTAIN 6 and PIONEER 6 assessing association between baseline kidney function and risk of MACE and effect of semaglutide on risk of MACE by baseline kidney function presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.